{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002940","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.043205+00:00","generated_at":"2026-05-16T10:49:30.339114+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"iBio raises $26M in PIPE led by Frazier Life Sciences to fund cardiometabolic programs","bullets":["Gross proceeds of ~$26M from sale of 11.06M shares/pre-funded warrants at $2.35/share.","Expected close on Jan 13, 2026; led by Frazier Life Sciences with other existing investors.","Proceeds to advance IBIO-610, IBIO-600, and myostatin/activin A bispecific programs.","Company expects cash runway extended into calendar 2028.","Leerink Partners lead placement agent; LifeSci Capital and Oppenheimer co-agents."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002940","json":"https://secwatch.observer/filing/0001104659-26-002940.json","markdown":"https://secwatch.observer/filing/0001104659-26-002940.md","text":"https://secwatch.observer/filing/0001104659-26-002940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926002940/0001104659-26-002940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926002940/tm262944d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:49:30.339114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"681f0fe0849cfa507a902ab1c072ee3c5507d2ee","claim":"iBio, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $26 million (effective 2026-01-08).","evidence_excerpt":"On January 8, 2026, iBio, Inc., a Delaware company (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a private placement priced at-the-market consistent with the rules of the Nasdaq Stock Market LLC (the “Private Placement”) an aggregate of 1,408,481 shares (the “Shares”) of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000110465926002940/0001104659-26-002940-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $26 million"},{"label":"Effective","value":"2026-01-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}